Wilson Health

wilsonhealth.org

At Wilson Health, improving the health of the community is at the heart of our mission. Our continued growth and expansion of health services and physicians, plus strong partnerships and collaborations, are all part of Wilson Health’s purpose to offer better healthcare to our communities, so people can spend more time doing what they love with those they love.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRY OUTLOOK

MUSTANG BIO ANNOUNCES STRATEGIC MANUFACTURING PARTNERSHIP AND PORTFOLIO UPDATES

Globenewswire | May 19, 2023

news image

Mustang Bio, Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (...

Read More

CELL AND GENE THERAPY

C-LECTA CONTINUES ITS GROWTH IN 2021 AND SEES ITSELF EXCELLENTLY POSITIONED FOR THE FUTURE WITH THE ENESYZ TECHNOLOGY PLATFORM

c-LEcta | December 20, 2021

news image

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...

Read More

MEDICAL

NUCLIXBIO ANNOUNCES A COLLABORATIVE RESEARCH AGREEMENT WITH PHARMABCINE

NuclixBio | March 15, 2022

news image

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™&#...

Read More

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

news image

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More
news image

INDUSTRY OUTLOOK

MUSTANG BIO ANNOUNCES STRATEGIC MANUFACTURING PARTNERSHIP AND PORTFOLIO UPDATES

Globenewswire | May 19, 2023

Mustang Bio, Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (...

Read More
news image

CELL AND GENE THERAPY

C-LECTA CONTINUES ITS GROWTH IN 2021 AND SEES ITSELF EXCELLENTLY POSITIONED FOR THE FUTURE WITH THE ENESYZ TECHNOLOGY PLATFORM

c-LEcta | December 20, 2021

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...

Read More
news image

MEDICAL

NUCLIXBIO ANNOUNCES A COLLABORATIVE RESEARCH AGREEMENT WITH PHARMABCINE

NuclixBio | March 15, 2022

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™&#...

Read More
news image

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More